company background image
APH

Alliance PharmaAIM:APH Stock Report

Market Cap

UK£546.9m

7D

-2.1%

1Y

38.3%

Updated

30 Nov, 2021

Data

Company Financials +
APH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends4/6

APH Stock Overview

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally.

Alliance Pharma Competitors

Charles River Laboratories International

NYSE:CRL

US$18.5b

Frontage Holdings

SEHK:1521

HK$8.7b

Price History & Performance

Summary of all time highs, changes and price drops for Alliance Pharma
Historical stock prices
Current Share PriceUK£1.02
52 Week HighUK£1.23
52 Week LowUK£0.72
Beta0.57
1 Month Change-0.97%
3 Month Change-5.74%
1 Year Change38.32%
3 Year Change49.71%
5 Year Change128.76%
Change since IPO409.00%

Recent News & Updates

May 28
An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Today we will run through one way of estimating the intrinsic value of Alliance Pharma plc ( LON:APH ) by taking the...

Mar 30
Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Shareholder Returns

APHGB PharmaceuticalsGB Market
7D-2.1%-1.6%-2.6%
1Y38.3%8.4%10.9%

Return vs Industry: APH exceeded the UK Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: APH exceeded the UK Market which returned 13.8% over the past year.

Price Volatility

Is APH's price volatile compared to industry and market?
APH volatility
APH Average Weekly Movement3.0%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: APH is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: APH's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996250Peter Butterfieldhttps://www.alliancepharmaceuticals.com

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products.

Alliance Pharma Fundamentals Summary

How do Alliance Pharma's earnings and revenue compare to its market cap?
APH fundamental statistics
Market CapUK£546.93m
Earnings (TTM)UK£18.04m
Revenue (TTM)UK£146.72m

30.3x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APH income statement (TTM)
RevenueUK£146.72m
Cost of RevenueUK£50.90m
Gross ProfitUK£95.83m
ExpensesUK£77.79m
EarningsUK£18.04m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.034
Gross Margin65.31%
Net Profit Margin12.29%
Debt/Equity Ratio47.4%

How did APH perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

48%

Payout Ratio

Does APH pay a reliable dividends?

See APH dividend history and benchmarks
When do you need to buy APH by to receive an upcoming dividend?
Alliance Pharma dividend dates
Ex Dividend DateDec 16 2021
Dividend Pay DateJan 07 2022
Days until Ex dividend15 days
Days until Dividend pay date37 days

Does APH pay a reliable dividends?

See APH dividend history and benchmarks

Valuation

Is Alliance Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: APH (£1.02) is trading below our estimate of fair value (£2.13)

Significantly Below Fair Value: APH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APH is poor value based on its PE Ratio (30.3x) compared to the UK Pharmaceuticals industry average (29.7x).

PE vs Market: APH is poor value based on its PE Ratio (30.3x) compared to the UK market (19x).


Price to Earnings Growth Ratio

PEG Ratio: APH is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: APH is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (4.5x).


Future Growth

How is Alliance Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

15.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APH's forecast earnings growth (15.7% per year) is above the savings rate (0.9%).

Earnings vs Market: APH's earnings (15.7% per year) are forecast to grow faster than the UK market (12.6% per year).

High Growth Earnings: APH's earnings are forecast to grow, but not significantly.

Revenue vs Market: APH's revenue (9.6% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: APH's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: APH's Return on Equity is forecast to be low in 3 years time (10.9%).


Past Performance

How has Alliance Pharma performed over the past 5 years?

-8.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APH has high quality earnings.

Growing Profit Margin: APH's current net profit margins (12.3%) are higher than last year (8.5%).


Past Earnings Growth Analysis

Earnings Trend: APH's earnings have declined by 8.9% per year over the past 5 years.

Accelerating Growth: APH's earnings growth over the past year (62.5%) exceeds its 5-year average (-8.9% per year).

Earnings vs Industry: APH earnings growth over the past year (62.5%) exceeded the Pharmaceuticals industry -20.6%.


Return on Equity

High ROE: APH's Return on Equity (6.4%) is considered low.


Financial Health

How is Alliance Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: APH's short term assets (£84.8M) exceed its short term liabilities (£38.5M).

Long Term Liabilities: APH's short term assets (£84.8M) do not cover its long term liabilities (£195.3M).


Debt to Equity History and Analysis

Debt Level: APH's net debt to equity ratio (37.6%) is considered satisfactory.

Reducing Debt: APH's debt to equity ratio has reduced from 49.7% to 47.4% over the past 5 years.

Debt Coverage: APH's debt is well covered by operating cash flow (29.7%).

Interest Coverage: APH's interest payments on its debt are well covered by EBIT (11.5x coverage).


Balance Sheet


Dividend

What is Alliance Pharma current dividend yield, its reliability and sustainability?

1.61%

Current Dividend Yield


Upcoming Dividend Payment

TodayDec 01 2021Ex Dividend DateDec 16 2021Dividend Pay DateJan 07 202222 days from Ex DividendBuy in the next 15 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: APH's dividend (1.61%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).

High Dividend: APH's dividend (1.61%) is low compared to the top 25% of dividend payers in the UK market (4.17%).


Stability and Growth of Payments

Stable Dividend: APH's dividend payments have been volatile in the past 10 years.

Growing Dividend: APH's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (48.4%), APH's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: APH's dividends in 3 years are forecast to be well covered by earnings (25.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Peter Butterfield (45 yo)

3.5yrs

Tenure

UK£612,034

Compensation

Mr. Peter Jonathan Butterfield has been Chief Executive Officer of Alliance Pharma plc since May 01, 2018. Mr. Butterfield served as Deputy Chief Executive Officer and Chief Operating Officer of Alliance P...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD810.37K) is about average for companies of similar size in the UK market ($USD1.03M).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APH's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: APH's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alliance Pharma plc's employee growth, exchange listings and data sources


Key Information

  • Name: Alliance Pharma plc
  • Ticker: APH
  • Exchange: AIM
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£546.929m
  • Shares outstanding: 537.26m
  • Website: https://www.alliancepharmaceuticals.com

Number of Employees


Location

  • Alliance Pharma plc
  • Avonbridge House
  • Bath Road
  • Chippenham
  • Wiltshire
  • SN15 2BB
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 21:42
End of Day Share Price2021/11/30 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.